Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

著者: Toby M. Maher, Tamera J. Corte, Aryeh Fischer, Michael Kreuter, David J. Lederer, María Molina‐Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Katerina Samara, Frank Gilberg, Vincent Cottin - The Lancet 2019 被引用: 630